Virtual Meetings 2022

Meet The Professor: Current and Future Management of Chronic Lymphocytic Leukemia

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Jennifer R Brown, MD, PhD
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
Boston, Massachusetts

Peter Hillmen, MB ChB, PhD
Professor of Experimental Haematology
University of Leeds
Honorary Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom

Susan O’Brien, MD
Professor, Division of Hematology/Oncology
School of Medicine
UCI Chao Family Comprehensive Cancer Center
Orange, California

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio



William G Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Additional faculty to be announced

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for chronic lymphocytic leukemia. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimizing the Selection of Therapy for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)

    MODULE 2: Toxicity and Tolerability Considerations with the Use of BTK and Bcl-2 Inhibitors for CLL

    MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory CLL

    MODULE 4: Novel Approaches Under Investigation in CLL

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives

  • Individualize the selection of systemic therapy for newly diagnosed CLL, considering each patient’s clinical presentation, biomarker profile, coexisting medical conditions and personal preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to evaluate and select available front-line options.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into treatment decision-making.
  • Appraise emerging Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies in the management of CLL.
  • Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and appropriately refer eligible patients for trial participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr BrownConsulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd, Bristol-Myers Squibb Company, Catapult Therapeutics, Genentech, a member of the Roche Group, HUTCHMED, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Lilly, MEI Pharma Inc, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Rigel Pharmaceuticals Inc; Contracted Research: Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Secura Bio, Sun Pharmaceutical Industries Ltd, TG Therapeutics Inc. Prof HillmenAdvisory Committee: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Sobi; Consulting Agreements: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Sobi; Contracted Research: AbbVie Inc, Apellis, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc; Speakers Bureau: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Roche Laboratories Inc, Sobi. Dr O’BrienConsulting Agreements: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, Aptose Biosciences Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Juno Therapeutics, a Celgene Company, Lilly, MEI Pharma Inc, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc, Vaniam Group, Verastem Inc, Vida Ventures; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Alliance Pharma, BeiGene Ltd, Caribou Biosciences Inc, Gilead Sciences Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mustang Bio, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc; Employment: University of California, Irvine. Dr RogersAdvisory Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Innate Pharma, Pharmacyclics LLC, an AbbVie Company; Consulting Agreement: Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Vincerx Pharma. Dr WierdaContracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor. Dr WoyachAdvisory Committee: BeiGene Ltd (Brukinsa); Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MorphoSys, Schrödinger, Verastem Inc.

SURVEY PARTICIPANTSMatthew S Davids, MD, MMScAdvisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Jeff Sharman, MDAdvisory Committee: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Genmab; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.